Joel Isaacson & Co’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$218K Sell
1,725
-33
-2% -$4.35K 0.01% 447
2026
Q1
$245K Buy
1,758
+33
+2% +$4.62K 0.01% 398
2025
Q4
$212K Buy
+1,725
New +$210K 0.01% 434
2017
Q1
Sell
-522
Closed -$37K 309
2016
Q4
$37K Sell
522
-714
-58% -$53.1K 0.01% 343
2016
Q3
$98K Sell
1,236
-74
-6% -$6.01K 0.02% 240
2016
Q2
$109K Buy
1,310
+226
+21% +$20.1K 0.02% 225
2016
Q1
$100K Buy
1,084
+1
+0.1% +$90 0.02% 241
2015
Q4
$110K Buy
1,083
+1
+0.1% +$104 0.03% 211
2015
Q3
$106K Sell
1,082
-119
-10% -$13.2K 0.03% 219
2015
Q2
$141K Buy
1,201
+36
+3% +$3.93K 0.04% 211
2015
Q1
$114K Buy
1,165
+955
+455% +$97K 0.03% 238
2014
Q4
$20K Hold
210
0.01% 431
2014
Q3
$22K Hold
210
0.01% 406
2014
Q2
$17K Hold
210
0.01% 424
2014
Q1
$15K Buy
210
+85
+68% +$6.67K 0.01% 441
2013
Q4
$9K Sell
125
-200
-62% -$13.9K ﹤0.01% 436
2013
Q3
$20K Hold
325
0.01% 363
2013
Q2
$17K Buy
+325
New +$16.9K 0.01% 344

Other funds holding GILD

Joel Isaacson & Co's GILD Position: Q2 2026 in Review

Joel Isaacson & Co reduced its Gilead Sciences (GILD) stake by 1.9% in Q2 2026, selling an estimated $4.35K and leaving 1,725 shares worth $218K. The position accounts for 0.01% of the portfolio, ranked #447.

Joel Isaacson & Co first reported a position in GILD in Q2 2013 and has held it in 18 quarters since. The position peaked at $245K in Q1 2026. 1,412 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Joel Isaacson & Co held 1,725 shares of Gilead Sciences worth $218K as of Q2 2026.
  • Joel Isaacson & Co sold 33 Gilead Sciences shares in Q2 2026, an estimated $4.35K.
  • Gilead Sciences made up 0.01% of Joel Isaacson & Co's portfolio in Q2 2026, its #447 holding.
  • Joel Isaacson & Co first reported a position in Gilead Sciences in Q2 2013 and has held it in 18 quarters since.
  • Joel Isaacson & Co's Gilead Sciences position peaked at $245K in Q1 2026.
  • 1,412 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Joel Isaacson & Co's 13F filing for Q2 2026, filed 4 Aug 2026.